Skip to main content

Drug Interactions between Krystexxa and Omontys

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

pegloticase peginesatide

Applies to: Krystexxa (pegloticase) and Omontys (peginesatide)

MONITOR: Antibodies that develop during pegloticase therapy may theoretically affect the pharmacologic effects of other pegylated agents. In clinical studies, anti-pegloticase antibodies developed in 92% of patients treated with pegloticase every 2 weeks, compared to 28% for placebo. Anti-PEG antibodies were also detected in 42% of patients treated with pegloticase. High anti-pegloticase antibody titer was associated with a failure to maintain pegloticase-induced normalization of uric acid. The impact of anti-PEG antibodies on the therapeutic response to other PEG-containing treatments is unknown. Because anti-pegloticase antibodies appear to bind to the PEG portion of the drug, there may be potential for binding with other pegylated products.

MANAGEMENT: Clinicians should be aware of the potential for diminished effects of other pegylated agents (including certain formulations of recombinant antihemophilic factor and coagulation factor IX as well as some liposomal formulations of chemotherapeutic agents such as doxorubicin and irinotecan) following treatment with pegloticase.

References

  1. (2010) "Product Information. Krystexxa (pegloticase)." Savient Pharmaceuticals

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer